{"title":"循环肿瘤 DNA 序列监测转移性食管鳞癌二线单药 tislelizumab 免疫疗法的复发和反应:一项前瞻性研究","authors":"Qiong He, Xun Shi, Junrong Yan, Mengmeng Wu, Cuiping Gu, Xinmin Yu","doi":"10.3892/mco.2024.2727","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Circulating tumor DNA serial monitoring of relapse and responses to tislelizumab immunotherapy as second‑line monotherapy for metastatic esophageal squamous cell carcinoma: A prospective study\",\"authors\":\"Qiong He, Xun Shi, Junrong Yan, Mengmeng Wu, Cuiping Gu, Xinmin Yu\",\"doi\":\"10.3892/mco.2024.2727\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":18737,\"journal\":{\"name\":\"Molecular and clinical oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-02-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular and clinical oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3892/mco.2024.2727\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular and clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3892/mco.2024.2727","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Circulating tumor DNA serial monitoring of relapse and responses to tislelizumab immunotherapy as second‑line monotherapy for metastatic esophageal squamous cell carcinoma: A prospective study